Engineered peptides can treat Ebola
UNMC researchers, led by Steven Hinrichs, M.D., Chair of the Department of Pathology and Microbiology, have developed antimicrobial peptides with efficacy against the Ebola virus.
The engineered peptides are derivatives of human LL-37 (Cathelicidin) and function by impairing the CatB-mediated cleavage of the viral glycoprotein; the process necessary for the virus to enter a host cell.
Such peptides could be used prophylactically to prevent Ebola, or therapeutically to treat the infection at a very early stage.
To discuss licensing opportunities contact Tyler Scherr, Ph.D., at email@example.com or 402-559-2140.